Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
SRA-515 by GSK for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
SRA-515 is under clinical development by GSK and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...
SRA-515 by GSK for Peritoneal Cancer: Likelihood of Approval
SRA-515 is under clinical development by GSK and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase I...
SRA-515 by GSK for Ovarian Cancer: Likelihood of Approval
SRA-515 is under clinical development by GSK and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I...
SRA-515 by GSK for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
SRA-515 is under clinical development by GSK and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
SRA-515 by GSK for Fallopian Tube Cancer: Likelihood of Approval
SRA-515 is under clinical development by GSK and currently in Phase I for Fallopian Tube Cancer. According to GlobalData, Phase...